SEC Form 4 · accession 0001178670-26-000047
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Cravatt
Director
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001178670
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $295.63 | Jun 1, 2026 | A | 4,393 | A | Jun 1, 2027 | Jun 1, 2036 | Common Stock | 4,393 | 4,393 | D |
Explanation of responses
- F1The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.